| What is the value of oncology medicines? | |
| | |
MedLine Citation:
|
PMID: 21057481 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Coverage with evidence development (CED), rather than quality-adjusted-life-year (QALY) thresholds, offers the best way forward in balancing evidence-based policy for new oncology products with the needs of developers, payers, physicians and patients. |
| | |
Authors:
|
Joshua Cohen; William Looney |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Nature biotechnology Volume: 28 ISSN: 1546-1696 ISO Abbreviation: Nat. Biotechnol. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-08 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9604648 Medline TA: Nat Biotechnol Country: United States |
Other Details:
|
Languages: eng Pagination: 1160-3 Citation Subset: IM |
Affiliation:
|
Tufts University School of Medicine, Center for the Study of Drug Development, Boston, Massachusetts, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A policy approach to the development of molecular diagnostic tests.
Next Document: Direct conversion of human fibroblasts to multilineage blood progenitors.